Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji

NCT07159373 is registered in ClinicalTrials.gov with Medicines Development for Global Health as lead sponsor.

NCT NCT07159373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07159373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy Trial of Mass Drug Administration With Moxidectin Versus Ivermectin in Combination With Diethylcarbamazine and Albendazole for Lymphatic Filariasis, Scabies, and Strongyloidiasis in Fiji
Lead sponsor
Medicines Development for Global Health
Phase
Phase 3
Overall status
Recruiting
Start date
September 28, 2026
Completion date
June 30, 2028
Enrollment
5,100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphatic filariasis, scabies, strongyloidiasis